RxDoctor Payments Data

Robin Caravallo

Acute Care · Aiea, HINPI 1851413892

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,035 of the $1,158 with a category attached, or 89.4%. It is spread thinly across 10 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $625, 4.9 times the $128 reported in 2021.

$1,158in general payments, 2019–2025

Across 12 payments — averaging $96.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$260
  • Pfizer$138
  • AstraZeneca$131
  • Regeneron Healthcare Solutions, Inc.$125
  • Seagen Inc.$124
  • Pharmaessentia USA Corporation$122
  • plus $258 from 4 others

What the payments were for

  • Food & beverage$1,03589%
  • Education$12311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,158 in reported general payments places this provider in the 80th percentile of 51 acute care providers in Hawaii.

See all acute care providers in Hawaii

Medicare billing

Part B allowed, 2024
$31,663
Medicare patients
231
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate30$529,750
XtandiEnzalutamide12$148,351
Abiraterone Acetate29$109,750
Anastrozole59$3,430
Exemestane22$2,798
Tamoxifen Citrate20$621
Letrozole18$453
Lidocaine Hcl ViscousLidocaine Hcl26$445
Alendronate Sodium20$320
Prednisone22$162
Potassium Chloride13$127
Oxycodone Hcl12$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$86$529,75030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 51 acute care providers in Hawaii.

Other acute care in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →